{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '13.0', 'Completion of the Study', 'The investigator will conduct the study in compliance with the protocol and complete the', 'study within the timeframe specified in the contract between the investigator (Director of', 'the Site in Japan) and AbbVie. Continuation of this study beyond this date must be', 'mutually agreed upon in writing by both the investigator (Director of the Site in Japan)', 'and AbbVie. The investigator will provide a final report to the IEC/IRB following', 'conclusion of the study, and will forward a copy of this report to AbbVie or their', 'representative.', 'The investigator (Director of the Site in Japan) must submit, maintain, and archive any', 'records related to the study according to ICH GCP and all other applicable regulatory', 'requirements. If the investigator (Director of the Site in Japan) is not able to retain the', 'records, he/she must notify Abb\u00b9 Vie to arrange alternative archiving options.', 'AbbVie will select the signatory investigator from the investigators who participate in the', 'study. Selection criteria for this investigator will include level of participation as well as', 'significant knowledge of the clinical research, investigational drug and study protocol.', 'The signatory investigator for the study will review and sign the final study report in', 'accordance with the European Agency for the Evaluation of Medicinal Products (EMEA)', \"Guidance on Investigator's Signature for Study Reports.\", \"The end-of-study is defined as the date of the last subject's last visit, or the date of the last\", \"subject's last survival follow-up contact, whichever is later.\", '113']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '14.0', \"Investigator's Agreement\", '1.', \"I have received and reviewed the Investigator's Brochure for rovalpituzumab\", 'tesirine and the product labeling for dexamethasone.', '2.', 'I have read this protocol and agree that the study is ethical.', '3.', 'I agree to conduct the study as outlined and in accordance with all applicable', 'regulations and guidelines.', '4.', 'I agree to maintain the confidentiality of all information received or developed in', 'connection with this protocol.', '5.', 'I agree that all electronic signatures will be considered the equivalent of a', 'handwritten signature and will be legally binding.', 'Protocol Title:', 'A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of', 'Rovalpituzumab Tesirine as Maintenance Therapy Following', 'First-Line Platinum-Based Chemotherapy in Subjects with Extensive', 'Stage Small Cell Lung Cancer (MERU)', 'Protocol Date:', '05 March 2019', 'Signature of Principal Investigator', 'Date', 'Name of Principal Investigator (printed or typed)', '114']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '15.0', 'Reference List', '1.', 'Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell', 'lung cancer in the United States over the last 30 years: analysis of the surveillance,', 'epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-44.', '2.', 'Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal', 'for clinicians. 2012;62(1):10-29.', '3.', 'Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer.', 'Crit Rev Oncol Hematol. 2004;49(2): 119-33.', '4.', 'Ready N, Pang H, Gu L, A, et al. Chemotherapy with or without maintenance', 'sunitinib for untreated extensive-stage small-cell lung cancer: a randomized,', 'double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin', 'Oncol. 2015;33(15):1660-5.', '5.', 'Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin', 'plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of', 'the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:2114-22.', '6.', 'Saunders L, Bankovich A, Anderson W, et al. A DLL3-targeted antibody-drug', 'conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells', 'in vivo. Science Transl Med. 2015;7(302):302ra136', '7. Chapman G, Sparrow D, Kremmer E, et al. Notch inhibition by the ligand delta-', 'like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal', 'dysostosis. Hum Mol Genet. 2011;20(5):905-16.', '8.', 'Dunwoodie S, Henrique D, Harrison S, et al. Mouse D113: a novel divergent Delta', 'gene which may complement the function of other Delta homologues during early', 'pattern formation in the mouse embryo. Development. 1997;124(16):3065-76.', '9.', 'Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-', 'targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-', 'human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42-51.', '115']\n\n###\n\n", "completion": "END"}